BioStock: Prolight Diagnostics advances towards validation of test for myocardial infarction diagnostics

Prolight Diagnostics’ report for the second quarter marks significant progress in developing the point-of-care analysis system Psyros. Not least, the company received a British grant of SEK 17 million, allowing them to initiate a pre-validation study on whole blood samples from patients with suspected myocardial infarction. The first results from the study are expected in the fourth quarter of 2024.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/09/prolight-diagnostics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se